Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting

Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs

Nutriband's AVERSA technology addresses the unmet need for safer abuse-deterrent transdermal patches

ORLANDO, FL / ACCESSWIRE / March 25, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure was presented at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting on March 8, 2024. The American Academy of Pain Medicine (AAPM) is dedicated to advancing multidisciplinary pain care, education, advocacy, and research.

The data indicate that transdermal patch abuse and accidental pediatric exposures to patches continue to be a serious problem resulting in major medical outcomes and death, suggesting an unmet need for safer abuse-deterrent versions of transdermal patches containing drugs with a risk of abuse, misuse or accidental exposure.

Nutriband's lead product is AVERSA Fentanyl which combines Nutriband's proprietary AVERSA abuse-deterrent transdermal technology with an already FDA-approved transdermal fentanyl patch and has the potential to become the world's first opioid patch with abuse-deterrent properties.AVERSA Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.¹

"As the data presented clearly illustrates, based on poison control call center information, abuse and overdose is a real problem with transdermal fentanyl as well as other transdermal opioid and stimulant products. Also, the incredible amount of accidental pediatric exposures, along with the major health outcomes associated with them, is alarming. We believe our Aversa abuse-deterrent technology will have a substantial impact on both of these unfortunate and preventable situations and will help reduce the risk of harm from fentanyl patches by providing taste aversion agents in every patch," said Gareth Sheridan, CEO, Nutriband.

Nutriband is developing its proprietary Aversa abuse-deterrent transdermal technology which can be incorporated into any transdermal patch that contains any drug with a risk of abuse, misuse or accidental exposure. Its Aversa product development pipeline includes abuse-deterrent versions of currently approved and marketed transdermal patches containing fentanyl, buprenorphine and methylphenidate which are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.